Rockwell Medical (RMTI) Q2 2024 earnings summary

Executive summary

• Achieved profitability on a cash flow and adjusted EBITDA basis for Q2 2024, marking a significant financial milestone and delivering on multi-year objectives.

• Net sales reached $25.8 million in Q2 2024, up 43% year-over-year, driven by value-based pricing, volume growth, and the Evoqua asset acquisition.

• Gross profit rose to $4.6 million in Q2 2024, up 341% year-over-year, with gross margin improving to 18% from 6% in Q2 2023.

• Net income for Q2 2024 was $0.3 million, a turnaround from a net loss of $3.3 million in Q2 2023.

• The company is the largest U.S. supplier of liquid bicarbonate concentrates and second largest for acid and dry bicarbonate concentrates.

Financial highlights

• Q2 2024 net sales: $25.8 million, up 14% sequentially and 43% year-over-year; six-month sales: $48.5 million, up 29% year-over-year.

• Q2 2024 gross profit: $4.6 million, up 48% from Q1 2024 and 341% year-over-year; six-month gross profit: $7.6 million, up 110% year-over-year.

• Q2 2024 net income: $0.3 million (vs. net loss of $3.3 million in Q2 2023); six-month net loss: $1.4 million (vs. $5.1 million loss in 2023).

• Q2 2024 EPS: $0.01 (Q2 2023: -$0.18); Q2 2024 adjusted EPS: $0.05 (Q2 2023: -$0.12).

• Cash and equivalents as of June 30, 2024: $11.9 million, up from $8.6 million at March 31, 2024; working capital: $14.9 million.

Outlook and guidance

• 2024 net sales guidance raised to $95–98 million, up from $90–94 million.

• 2024 gross profit guidance increased to $14–16 million, gross margin 14%–17%, and adjusted EBITDA $750,000–$1.5 million.

• Gross margin expected to reach ~20% in 2025 and above 25% in 2026.

• Management expects current working capital to cover at least 12 months of operations.

• Focus for 2025 and beyond is on growing the concentrates business, expanding into new product lines, and transferring Evoqua manufacturing in-house.